Meanwhile, the net profit of the first half of the world's non-recurrent profit is 18,781.510,000 yuan, accounting for 2018 full-year results of a commitment of 380 million Yuan 49.43%. The largest m
Medical Network September 6 September 4 evening, the Blue Sail medical released the announcement that the company to 18.58 yuan/share price, the successful issuance of 98.871 million shares, a total of 1.837 billion yuan, the funds raised will be used for the acquisition of Bai Sheng International need to Temasek and other foreign shareholders to pay the cash price.
This marks the blue Sail medical acquisition of the last step of the international deal--supporting financing formally completed implementation. The announcement shows that the issue price of Blue sail medical treatment is 18.58 yuan/share, which is obviously higher than the average of 18.27 yuan/share of the first 20 trading days before the date of issuance of the CSRC rules. In view of this, some market participants believe that this shows that investors are more enthusiastic about the Yu Lanfan.
In the recent downturn in the market environment is not easy.
In August, the only single non-controlling shareholder subscribed to the cash-type directional issuance
The announcement shows that the Blue Sail Medical Service was approved by the SFC on May 10 this year, the approval is valid for 12 months, and the company finally completed the entire fundraising in only 3 months. Since the introduction of new regulations in the two quarter of this year, banks, trusts and other past sources of funds to the stock market has been nearly cut off the market funds sharply reduced.
At the same time, the overall performance of the stock market continued to be weak, investors ' confidence was depressed, and there were more losses in previous projects, which led to a significant decrease in the willingness of investment institutions to participate. Wind information data shows that in the first August of this year, the cash subscription of listed companies in the first year of the project amounted to 80, down 30% yoy. The total of these projects is expected to raise 155.452 billion yuan, the actual raise of only 124.502 billion yuan, the actual raise rate of 80%, and this figure in the same period last year as high as 98%.
Split to each project to see that the full project is only 36, less than half of all projects, the minimum amount of the actual raise is only 10% of the estimated amount. Especially since June, the issuance and implementation of listed companies has been significantly deteriorated.
In June alone, 30 companies were unable to complete the issuance of the approval or announced the termination of the fixed increase and withdrew the relevant application, since August there have been 10 companies announced the termination of the fixed increase matters. Lan Fan Medical This increase, is a a-share market since August, the only single non-controlling shareholder subscription of cash category increase (August total of 2 single cash category increase, another single cash category increase is a total of 86% of the controlling shareholder and associated shareholders subscription of the long-power technology (600584 announcements, quotes, reviews, financial reports), institutional investors only subscribed to 500 million yuan ), and the company will be able to achieve such a large amount of funds in three months after the approval, the issue is quite smooth.
Especially in the medical industry listed companies affected by the vaccine incident, the valuation of the general correction, the company can still be less than 10% discount rate to attract close to the approval of the purchase of funds, and willingly locked 24 months, showing the company's solid fundamentals have been recognized by the market.
Biosensors International help Blue Sail Medical layout high value consumables
The announcement shows that blue Sail medical headquarters is located in Zibo, Shandong Province, Medical devices Invisible Champion in the field of low-value consumables. As a global market share of PVC glove industry leader, with a sound global sales channels, good cost control and fine management capabilities for the industry praised.
Last year, the company acquired the world's leading cardiovascular high-value consumables platform by acquiring the opportunity of the Singapore multinational Equipment company, Kashiwa-Sheng International, with significant long-term development potential.
It is understood that biosensors international core products drug-coated stent biofreedomtm, drug-eluting stent EXCROSSALTM and other clinical experimental data excellent, technical advantages are obvious, the company in the new account of the overall increase in the dividend period, long-term development potential is obvious.
At the same time, the future company will be around the cardiovascular department platform to independent Research and development and investment incubation, the use of their own global layout of the outstanding advantages of the sales network, and constantly enrich the expansion of product lines. According to the company's semi-annual report, the first half of 2018, the blue Sail medical operation revenue of 968 million yuan, attributable to the shareholders of the listed companies of the net profit of 148 million yuan, this time only to merge with the June sales data of the international Group, However, the net profit attributable to the shareholders of the listed companies increased by 24% and 42.9% respectively over a year earlier.
Meanwhile, the net profit of the first half of the world's non-recurrent profit is 18,781.510,000 yuan, accounting for 2018 full-year results of a commitment of 380 million Yuan 49.43%. The largest medical device merger in a A-share history | Lan Fan Medical successfully completed acquisition of Biosensors